Novartis has opened a new manufacturing facility for cell and gene therapies in Switzerland. In addition to manufacturing areas for novel CAR-T cell therapies, the new building also hosts the production of innovative, difficult-to-manufacture solid dosage forms such as tablets and capsules. In September 2019, the first clinical production of a cell and gene therapy batch was successfully completed. The $90 million facility is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020. The Swiss facility, as well as a separate French site also being expanded, are central to Novartis’s plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises. Learn More